This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
YY1 / Transcriptional repressor protein YY1 · IHC design guide
Design Immunohistochemistry for YY1
Plan YY1 chromogenic IHC in paraffin sections around its widespread nuclear pattern (HPA tissue IHC). Use high-staining follicle cells or urothelial cells as positive controls, and assess signal in nuclei (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
YY1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining across tissues (HPA tissue IHC) | |
| Staining pattern | Widespread nuclear staining in tissue cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00833-3) | |
| Positive control | Ovary+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | HPA staining may reflect proteins from more than one gene (HPA tissue IHC) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | No isoforms annotated; one 1–414 chain (UniProt) |
Section 1
Recommended YY1 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet: M00833-3). The published chromogenic IHC protocols below provide YY1 staining conditions for gastric and esophageal tissue (PMC12754092; PMC3986816; PMC4196789).
| Sample | Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet M00833-3) |
| Fixation | Image fixative and duration unreported (datasheet M00833-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00833-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00833-3) |
| Primary antibody | Mouse monoclonal (clone 3F3E7) anti-YY1, 2 μg/ml (datasheet M00833-3) |
| Primary incubation | Overnight at 4 °C (datasheet M00833-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00833-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | YY1-positive staining in follicle cells of ovary (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 for the catalog antibody (datasheet: M00833-3); the cited studies used citrate or EDTA retrieval with their respective antibodies (PMC12754092; PMC3986816; PMC4196789).
Section 2
What Is the Expected YY1 Staining Pattern?
YY1 is associated with the nuclear matrix (UniProt P25490) and shows ubiquitous nuclear staining in tissue IHC (HPA: Supported reliability). Expect stained nuclei across many cell types, with intensity varying by tissue: follicle cells, cytotrophoblasts, peritubular cells and urothelial cells are reported as High (HPA tissue IHC). YY1 has no transmembrane segment (UniProt P25490 topology).
| Discrete nuclear chromogen in the expected cells, with some nuclei darker than others. | This fits the ubiquitous nuclear profile; intensity need not be uniform across tissues or cell populations (HPA tissue IHC). Score the fraction of stained nuclei and nuclear intensity separately, using the same scoring approach across sections (standard IHC practice). |
| Strong cytoplasmic or membrane staining with little nuclear staining. | Treat this as an unexpected compartment pattern: YY1 is nuclear matrix associated and lacks a transmembrane segment (UniProt P25490). Review the negative control, detection background and antibody conditions before interpreting the extranuclear signal as YY1 (standard IHC practice). |
| An unexpected cell population stains more strongly than the mapped population. | Check cell identity and compartment before calling it positive: HPA reports ubiquitous nuclear expression, so an unlisted stained cell type alone does not establish an error (HPA tissue IHC). Staining confined to unexpected cells, especially outside nuclei, warrants checks for cross-reactivity or endogenous detection activity (standard IHC practice). |
| Diffuse colour covers nuclei, cytoplasm and surrounding tissue. | Diffuse staining is difficult to score as nuclear YY1 and may reflect detection background or inadequate blocking or washing (standard IHC practice). Compare with a section processed without primary antibody; HPA describes a nuclear tissue pattern (HPA tissue IHC). |
| No nuclear signal appears in a section expected to stain strongly. | An absent signal in a high-staining HPA population, such as placental cytotrophoblasts, suggests a run or specimen issue before a biological negative is assigned (HPA: High in cytotrophoblasts; standard IHC practice). Check a known-positive control processed with the same run. |
💡Expected YY1 appearanceCall a result positive when interpretable cell nuclei show discrete chromogen, with strong nuclear staining possible in HPA High populations such as urothelial cells; diffuse extranuclear colour alone is an unconvincing positive (HPA tissue IHC; standard IHC practice).
| Tissue and cell choice | HPA reports High staining in ovarian follicle cells, placental cytotrophoblasts, testicular peritubular cells and bladder urothelial cells, but Low staining in hepatocytes and several listed neural populations (HPA tissue IHC). A faint result in a Low population therefore has less diagnostic value than a failed High control. |
| Antibody evidence and specificity | Two listed antibodies have Supported IHC status, while the tissue profile carries Supported reliability (HPA antibodies; HPA tissue IHC). HPA also cautions that the assay targets protein from more than one gene; nuclear staining supports a YY1 compatible pattern but does not, by itself, establish exclusive molecular identity (HPA tissue IHC). |
| IF/ICC Q&A: Where should fluorescence appear? | Mainly in the nucleoplasm, with additional signal reported at nucleoli fibrillar centers and nuclear bodies (HPA subcellular ICC-IF). That cell imaging detail helps assess compartment plausibility; it should not be required as a separately resolved pattern in chromogenic tissue IHC (HPA subcellular ICC-IF; standard IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| A High tissue control has no nuclear staining. | A staining-run problem is possible when an HPA High population is blank (HPA tissue IHC; standard IHC practice). | Review the run's positive control and reagent sequence, then assess retrieval and primary-antibody conditions as general IHC variables (standard IHC practice). No YY1-specific retrieval or fixation sensitivity is established by these sources. |
| Staining is weak in hepatocytes or listed neural populations. | Those populations are reported as Low by HPA (HPA tissue IHC). | Compare with a High population from the same run before changing conditions; interpret the weak signal in its cell and tissue context (HPA tissue IHC; standard IHC practice). |
| Cytoplasmic staining dominates the section. | That distribution conflicts with the reported nuclear localization (UniProt P25490; HPA tissue IHC). | Compare a no-primary control and a known-positive section, then review antibody dilution and wash conditions for nonspecific staining (standard IHC practice). |
| Diffuse chromogen obscures nuclear borders. | High background can obscure compartment scoring (standard IHC practice). | Inspect the no-primary control; review blocking, wash steps and detection development as general chromogenic IHC checks (standard IHC practice). |
| Colour persists in a no-primary control. | Primary-independent colour can arise from endogenous detection activity or the detection system (standard IHC practice). | Address the detection-system background using its appropriate control and blocking steps before scoring YY1 (standard IHC practice). |
| Only an unexpected cell population appears strongly positive. | HPA reports ubiquitous nuclear expression and cautions that staining may target protein from more than one gene; cell identity and specificity need review (HPA tissue IHC). | Confirm the stained cells on the counterstain, compare compartment and expected HPA populations, and review controls or an independently validated antibody if specificity remains uncertain (HPA tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing YY1 staining
M00833-3 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-3). YY1 was detected in a paraffin-embedded section of human thyroid cancer tissue. Heat
M00833-3 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-3). YY1 was detected in a paraffin-embedded section of human laryngeal squamous cell car
M00833-3 · IFIF analysis of YY1 using anti-YY1 antibody (M00179-1). YY1 was detected in an immunocytochemical section of T-47D cells. Enzyme antigen retr
M00833-2 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-2). YY1 was detected in a paraffin-embedded section of human thyroid cancer tissue. Heat
M00833-2 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-2). YY1 was detected in a paraffin-embedded section of human pancreatic ductal adenocarc
M00833-1 · IHCIHC analysis of YY1 using anti-YY1 antibody (M00833-1). YY1 was detected in a paraffin-embedded section of human laryngeal squamous cell car
M00833 · IHCImmunohistochemical analysis of paraffin-embedded human bladder using YY1 Antibody.
M00833 · IFImmunofluorescent analysis using the Antibody at 1:50 dilution.
PB9909 · IFIF analysis of YY1 using anti-YY1 antibody (PB9909). YY1 was detected in immunocytochemical section of A431 cells. Enzyme antigen retrieval
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/cerebral+cortex#imid_375182
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/colon#imid_375116
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/liver#imid_375109
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100811-YY1/tissue/kidney#imid_375110
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA000597; green = YY1, blue = nucleus, red = microtubules.
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA000597; green = YY1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for YY1 IHC & IF
🧪Run ovary first; follicle cells should show YY1 staining (HPA: High in ovary follicle cells). HPA detects YY1 in all 45 scored tissues, so use no-primary and isotype controls for the negative comparison; no validated YY1-negative cell type within the ovary section is identified in the supplied evidence (HPA: no negative tissue rows).
Positive control tissue: Ovary (Follicle cells, HPA High)
Negative control tissue: None in HPA: YY1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show YY1 in REH, Rh30, U2OS, A-431, U-251MG, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section, an isotype control matched to the mouse primary’s immunoglobulin class, and a matched YY1-knockout biological control if available (caption: mouse anti-YY1; standard IHC control practice). For ovary, quench endogenous peroxidase and check background in the no-primary section before interpreting HRP/DAB staining (caption: HRP/DAB; standard chromogenic IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected M00833-3 paraffin-section caption does not state the fixative (caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required; the relative ease of frozen-section IHC or IF cannot be determined from the supplied evidence (caption: EDTA retrieval; HPA: ICC-IF localization). No ovary-specific artefact is documented in the supplied evidence; assess endogenous peroxidase background with the no-primary control (HPA: ovary follicle-cell staining; standard chromogenic IHC practice).
HPA tissue IHC evidence for YY1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Ovary | Follicle cells | High | Protein (IHC) | HPA → |
| Placenta | Cytotrophoblasts | High | Protein (IHC) | HPA → |
| Testis | Peritubular cells | High | Protein (IHC) | HPA → |
| Urinary bladder | Urothelial cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: YY1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced YY1 IHC Tips
Troubleshoot YY1 staining in paraffin sections by checking retrieval, nuclear localisation and controls before comparing chromogenic IHC results (datasheet M00833-3; UniProt P25490).
What retrieval should I use when YY1 nuclear staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 for the catalog antibody on paraffin sections (datasheet M00833-3). The demonstrated tissue workflow then used 2 μg/ml primary antibody overnight at 4°C, so check those conditions before changing retrieval (datasheet M00833-3). Compare a retrieval time series on adjacent sections while holding detection and exposure to DAB constant; excessive heating can damage morphology and complicate nuclear scoring (standard IHC practice). If staining remains weak, test an alternative retrieval buffer as a documented fallback alongside EDTA pH 8.0, with a positive control on each run (standard IHC practice; datasheet M00833-3).
Could fixation explain weak or patchy YY1 staining?
The selected tissue caption identifies a paraffin section but does not state its fixative, so YY1-specific fixation sensitivity is unknown for this antibody (datasheet M00833-3). Record fixative, fixation duration, section age and processing history before comparing cases, because these variables can change epitope accessibility in IHC (standard IHC practice). When troubleshooting, stain matched sections from the same block together and include a known staining control to separate processing variation from detection variation (standard IHC practice). Do not infer a preferred fixative from YY1 phosphorylation sites, its lack of a transmembrane segment or the HPA tissue pattern (UniProt P25490; HPA tissue IHC).
Where should YY1 staining appear in a convincing IHC section?
Assess YY1 primarily in nuclei: UniProt associates it with the nuclear matrix, and HPA reports ubiquitous nuclear tissue staining (UniProt P25490; HPA tissue IHC). HPA cell imaging further places it mainly in the nucleoplasm, with additional signal in nucleolar fibrillar centers and nuclear bodies (HPA subcellular). Use a nuclear counterstain to identify intact nuclei, then judge whether DAB overlaps those nuclei across well-preserved regions (standard IHC practice). Predominantly diffuse cytoplasmic, membranous or extracellular colour needs control-based investigation before it is scored as YY1; the protein has no annotated transmembrane segment (UniProt P25490; standard IHC practice).
How can I assess epitope uncertainty when YY1 staining differs between samples?
The supplied record lists one YY1 chain, residues 1–414, and no annotated isoforms; this does not establish which epitope the catalog antibody detects (UniProt P25490; datasheet M00833-3). YY1 has reported phosphorylation at residues 118, 187, 247 and 378, but no supplied evidence links these modifications to this antibody’s IHC signal (UniProt P25490). Check the antibody’s epitope documentation if available, and compare staining with an independently validated YY1 antibody targeting a distinct region (standard IHC practice). Keep retrieval and detection matched across serial sections, since technical differences can mimic sample-dependent epitope loss (standard IHC practice).
How should I investigate a YY1 IHC pattern using multiplex IF?
Treat multiplex IF as a separate validation experiment rather than transferring the paraffin IHC conditions directly; the selected caption documents chromogenic detection only (datasheet M00833-3). Pair YY1 with a marker for the expected cell type in the sampled tissue and use a nuclear counterstain to assign YY1 signal to individual nuclei (standard IF practice; HPA tissue IHC). Choose fluorophores in channels with low tissue autofluorescence and include unstained and single-stain controls before interpreting colocalisation (standard IF practice). YY1 lacks a transmembrane segment and is nuclear, so permeabilise sufficiently for access to the nuclear epitope while checking that nuclear morphology remains intact (UniProt P25490; standard IF practice).
How do I reduce diffuse DAB background without losing nuclear YY1?
First inspect a no-primary control for endogenous peroxidase activity and nonspecific detection, especially when colour extends beyond nuclei (standard IHC practice; UniProt P25490). Peroxidase blocking is a general chromogenic IHC step; the selected YY1 caption reports a peroxidase-conjugated secondary and DAB but does not specify a peroxidase block (standard IHC practice; datasheet M00833-3). Its demonstrated blocking step used 10% goat serum, followed by 2 μg/ml primary overnight at 4°C (datasheet M00833-3). If background persists, titrate primary concentration and DAB development on matched sections, retaining a positive control to detect lost nuclear sensitivity (standard IHC practice).
What should I score when comparing YY1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the analysis region and cell population before scoring, then count only interpretable nuclei within intact tissue (standard IHC practice; UniProt P25490). Report the percentage of positive nuclei and, when intensity matters, a nuclear H-score from 0–300 using intensity grades 0–3 (standard IHC practice). For spatial comparisons, positive nuclei per mm² can be useful, but normalise this density to the number of eligible cells or nuclei in the same region (standard IHC practice). Keep retrieval, section handling, detection and scoring thresholds consistent across samples; HPA describes broad nuclear expression rather than a universal negative tissue control (standard IHC practice; HPA tissue IHC).
How can I distinguish genuine YY1 positivity from artefact?
Expect staining in nuclei of viable cells: HPA describes ubiquitous nuclear expression, while UniProt associates YY1 with the nuclear matrix (HPA tissue IHC; UniProt P25490). Compare the signal with nuclear counterstain and a no-primary control, and exclude folds, tissue edges, necrotic areas and isolated DAB deposits from scoring (standard IHC practice). Diffuse staining in the wrong compartment or colour reproduced in the no-primary control suggests a detection artefact, including endogenous enzyme activity (standard IHC practice; UniProt P25490). HPA reports high staining in ovarian follicle cells, placental cytotrophoblasts, testicular peritubular cells and bladder urothelial cells, but cautions that its antibody may detect proteins from more than one gene (HPA tissue IHC).
Boster reagents
Best YY1 / Transcriptional repressor protein YY1 IHC Antibodies
Anti-YY1 antibodies have IHC images from human paraffin sections and an IF image from A431 cells (catalog image captions); the catalog lists human, mouse and rat reactivity (catalog applications and reactivity).
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 3F3E7)
Cat # M00833-3
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 2C10F9)
Cat # M00833-2
Real IHC data
Anti-YY1 Antibody ® (monoclonal, 6H3E1)
Cat # M00833-1
Real IHC data
Anti-YY1 Rabbit Monoclonal Antibody
Cat # M00833
Real IF data
Anti-YY1 Antibody ®
Cat # PB9909
M00833-3 and M00833-2 show IHC in human thyroid cancer sections; M00833-1 shows human laryngeal squamous cell carcinoma, and M00833 shows human bladder (each SKU’s IHC image caption). PB9909 shows IF in A431 cells (PB9909 IF image caption).
Which to pick: For tissue IHC, choose a SKU with an image from the relevant paraffin section: M00833-3, M00833-2, M00833-1 or M00833 (each SKU’s IHC image caption); the captions do not report the fixative. For IF/ICC, PB9909 has both applications listed and an A431 IF image (PB9909 catalog applications and IF image caption). For work across species, M00833 is a rabbit monoclonal with IHC and IF listed and human, mouse and rat reactivity (M00833 catalog); its IHC image documents a human paraffin section only (M00833 IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P25490 (TYY1_HUMAN, Transcriptional repressor protein YY1).
- Human Protein Atlas. YY1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. YY1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the nucleoli fibrillar center and nuclear bodies..
- Human Protein Atlas. YY1 antibody validation summary (3 antibodies).
- YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice. Nature communications 2025 — PMC12234789.
- Yin Yang 1 activates JAK-STAT3-mediated epithelial-mesenchymal transition in Helicobacter pylori-induced gastric cancer progression. World journal of clinical oncology 2025 — PMC12754092.
- Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. Journal of translational medicine 2014 — PMC3986816.
- Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas. OncoTargets and therapy 2014 — PMC4196789.
- PubMed PMID:1655281 — UniProt-cited evidence.
- PubMed PMID:1946405 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for YY1 (Transcriptional repressor protein YY1). Expected localisation Nuclear staining across tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00833-3). Validated IHC antibody: M00833-3 at 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Ovary (Follicle cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet M00833-3); 2. Fixation: Image fixative and duration unreported (datasheet M00833-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00833-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00833-3); 8. Primary antibody: Mouse monoclonal (clone 3F3E7) anti-YY1, 2 μg/ml (datasheet M00833-3); 9. Primary incubation: Overnight at 4 °C (datasheet M00833-3). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: HPA staining may reflect proteins from more than one gene (HPA tissue IHC); Isoform / epitope: No isoforms annotated; one 1–414 chain (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt P25490, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00833-3, PMC12754092, PMC3986816. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/YY1/immunohistochemistry-ihc-guide.